ADGRG6 and pancreatic adenocarcinoma: Although xenograft findings require validation in immunocompetent models, our results highlight ADGRG6 as a potential oncogenic driver and therapeutic target in PAAD, linking tumor-intrinsic growth mechanisms with immune modulation within the TME.